…But Not Yet for Everyone
However, today’s immunotherapies don’t work for everyone and experts don’t yet know why, or how to predict which patients will do well on them. What’s more, some types of cancer are more susceptible to immunotherapythan others. So-called hot, or inflamed, tumors with many mutations respond better to checkpoint inhibitors than “cold” tumors that don’t attract immune cells. Current CAR-T therapies work well against blood cancers but not against solid tumors. Unfortunately, people with some of the most common cancers (such as breast and prostate cancer) and hard-to-treat cancers (like pancreatic cancer) usually don’t respond to existing immunotherapies.
